These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 11925325)

  • 41. [Neurobiology in the neuropharmacology of antipsychotic drugs].
    Tassin JP
    Encephale; 2006 Jan; 32 Pt 2():S6-7. PubMed ID: 16800077
    [No Abstract]   [Full Text] [Related]  

  • 42. [The maintenance dosage of neuroleptic agents].
    Stolk PJ
    Ned Tijdschr Geneeskd; 1987 Jul; 131(27):1158-9. PubMed ID: 2886929
    [No Abstract]   [Full Text] [Related]  

  • 43. Acute pancreatitis associated with quetiapine use in schizophrenia.
    Chang TG; Chiu NY; Hsu WY
    J Clin Psychopharmacol; 2014 Jun; 34(3):382-3. PubMed ID: 24699039
    [No Abstract]   [Full Text] [Related]  

  • 44. Visual processing and social cognition in schizophrenia: relationships among eye movements, biological motion perception, and empathy.
    Matsumoto Y; Takahashi H; Murai T; Takahashi H
    Neurosci Res; 2015 Jan; 90():95-100. PubMed ID: 25449145
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pathological gambling and compulsive eating associated with aripiprazole.
    Roxanas MG
    Aust N Z J Psychiatry; 2010 Mar; 44(3):291. PubMed ID: 20180730
    [No Abstract]   [Full Text] [Related]  

  • 46. An experimental test of two opposing theories of the perception deficit in schizophrenia.
    Meadow A; Donlon P; Wahba M; Tupin JP
    J Clin Psychol; 1979 Oct; 35(4):707-12. PubMed ID: 511994
    [No Abstract]   [Full Text] [Related]  

  • 47. Attention for movement production: Abnormal profiles in schizophrenia.
    Delevoye-Turrell YN; Thomas P; Giersch A
    Schizophr Res; 2006 Jun; 84(2-3):430-2. PubMed ID: 16580818
    [No Abstract]   [Full Text] [Related]  

  • 48. Pathophysiology of schizophrenia - causal role for dopamine or noradrenaline?
    Iversen LL; Reynolds GP; Snyder SH
    Nature; 1983 Oct 13-19; 305(5935):577-8. PubMed ID: 6137773
    [No Abstract]   [Full Text] [Related]  

  • 49. Schizophrenia and evoked potentials: maximum amplitude, frequency of peaks, variability, and phenothiazine effects.
    Rappaport M; Hopkins HK; Hall K; Belleza T; Hall RA
    Psychophysiology; 1975 Mar; 12(2):196-207. PubMed ID: 237296
    [No Abstract]   [Full Text] [Related]  

  • 50. The role of neural mechanisms of attention in solving the binding problem.
    Reynolds JH; Desimone R
    Neuron; 1999 Sep; 24(1):19-29, 111-25. PubMed ID: 10677024
    [No Abstract]   [Full Text] [Related]  

  • 51. Visual Impairments in Schizophrenia: Their Significance and Unrealized Clinical Potential.
    Silverstein SM; Keane BP; Demmin DL; Fradkin SI
    Psychiatr Danub; 2020; 32(1):72-73. PubMed ID: 32303033
    [No Abstract]   [Full Text] [Related]  

  • 52. A strategy for the study of behavioral mechanisms of antipsychotic drug action in schizophrenia.
    Spohn HE
    Psychopharmacologia; 1972; 24(1):201-8. PubMed ID: 5018523
    [No Abstract]   [Full Text] [Related]  

  • 53. The temporal correlation hypothesis of visual feature integration: still alive and well.
    Gray CM
    Neuron; 1999 Sep; 24(1):31-47, 111-25. PubMed ID: 10677025
    [No Abstract]   [Full Text] [Related]  

  • 54. [Evaluation of ophthalmic toxicity].
    Sato S
    Nihon Yakurigaku Zasshi; 2008 Jan; 131(1):50-4. PubMed ID: 18187885
    [No Abstract]   [Full Text] [Related]  

  • 55. Windows to the soul: vision science as a tool for studying biological mechanisms of information processing deficits in schizophrenia.
    Yoon JH; Sheremata SL; Rokem A; Silver MA
    Front Psychol; 2013 Oct; 4():681. PubMed ID: 24198792
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Early-stage vision and schizophrenia.
    Kéri S; Janka Z; Benedek G
    Am J Psychiatry; 2002 Apr; 159(4):678; author reply 678-9. PubMed ID: 11925325
    [No Abstract]   [Full Text] [Related]  

  • 57. [The Spatial-Frequency Characteristics of the Visual System in Schizophrenia].
    Shoshina II; Shelepin YE; Vershinina EA; Novikova KO
    Fiziol Cheloveka; 2015; 41(3):29-40. PubMed ID: 26237946
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Visual perception in medicated schizophrenic patients.
    Schwartz B; Winstead DK
    Am J Psychiatry; 1997 Apr; 154(4):585-7. PubMed ID: 9090363
    [No Abstract]   [Full Text] [Related]  

  • 59. Visual masking in schizophrenia: overview and theoretical implications.
    Green MF; Lee J; Wynn JK; Mathis KI
    Schizophr Bull; 2011 Jul; 37(4):700-8. PubMed ID: 21606322
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The frequency-contrast sensitivity of visual stimulus perception in patients with schizophrenia with the therapy of atypical and typical antipsychotic drugs].
    Shoshina II; Shelepin IuE; Semenova NB
    Fiziol Cheloveka; 2014; 40(1):43-8. PubMed ID: 25272767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.